Systematic nurse-led consultations based on electronic patient-reported outcomes for women with endometrial or ovarian cancer during chemotherapy-a feasibility study

基于电子患者报告结果的护士主导的系统性咨询在子宫内膜癌或卵巢癌化疗女性患者中的应用——一项可行性研究

阅读:1

Abstract

PURPOSE: This study aimed to investigate the feasibility of nurse-led consultations based on ePRO for women with endometrial or ovarian cancer receiving chemotherapy. METHODS: This was a prospective single-cohort feasibility study. The patients responded to weekly ePRO using the Elekta Kaiku platform, which was adapted to Danish. At selected time points during chemotherapy, nurses conducted nurse-led consultations replacing physicians. The primary outcome was the patient completion rate of ePRO reporting in the Elekta Kaiku platform. Secondary outcomes included assessing safety, acceptability, practicability, usability, patient satisfaction with ePRO, and patient symptom burden. RESULTS: Twenty patients were included, with a mean age of 59 years. A total of 320 ePRO reports were received, equivalent to an ePRO response of 18 times per patient during six cycles of chemotherapy. The results showed a high weekly completion rate (87%), high patient satisfaction with ePRO, and a continuous high symptom burden. Nurse-led consultations achieved a success rate of 55% in adhering to scheduled appointments. The primary contributing factors to this issue were the inadequate internal workflows and the complex symptom burden experienced by the patients. CONCLUSION: This study indicates that weekly ePRO reporting in conjunction with nurse-led consultations may be feasible in this population. The use of ePRO revealed a high level of symptoms reported by patients throughout the treatment cycles. The results emphasize the importance of clinicians in proactively and systematically intervening at an early stage to prevent symptom escalation. However, the small sample size limits the generalizability of this study. TRIAL REGISTRATION: This study was registered at the Capital Region of Denmark (P-2021-179) and approved the 10/03/2021. ClinicalTtrials.gov ID: NTCC04945187.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。